Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- Kate Farms Inc
- Study ID
- NCT07234825
- Status
- Recruiting
Conditions
- Eosinophilic Esophagitis (EoE)
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Partial enteral nutrition (PEN) with dairy elimination — OTHERPatients in the PEN with dairy elimination group will receive 50% calories from Kate Farms Standard 1.2 formula and 50% dairy free regular diet.
- Dairy elimination alone — OTHERParticipants in this group will be on a dairy-free regular diet alone.
Study Details
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut microbiota, and environmental toxin exposures.
Key Dates
- Start date
- Mar 18, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- No Intervention: Control12 participants will be control subjects without diagnosis of EoE
- Experimental: Dairy Free12 subjects will be enrolled in the dairy free diet group.
- Experimental: Dairy free + Partial Enteral Nutrition (PEN) diet12 subjects will be enrolled in the diary free and 50% PEN diet
Primary Outcome Measure
Feasibility of PEN assessed by 3-day diet record [ Time Frame: 3 months ]
Central Contacts
- Danny Gagucas206-987-1062
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Seattle Children's Hospital | Seattle | Washington | 98105 | Elizabeth Reznikov, DO, PhD (SUB_INVESTIGATOR) Michael Pickens, DO (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Seattle, WA
By research site
Related Studies
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of CareRecruiting · Regeneron Pharmaceuticals · Phoenix, Arizona
- Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral ImmunotherapyRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)PHASE4 · Recruiting · University of California, San Diego · La Jolla, California
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisPHASE3 · Recruiting · Regeneron Pharmaceuticals · Phoenix, Arizona